The nameplate is a folded flower - half open, half held back. A fitting mark for a company that goes looking for the drugs everyone else set down, and tries to finish what someone else started.
There are, by most counts, around 7,000 rare diseases. Fewer than one in twenty has an approved treatment. The reason is not, mostly, that the science is missing. It is that the science is stranded - sitting in an academic lab that ran out of grant money, or in a small biotech that pivoted, or inside a big pharma portfolio where a promising molecule lost an internal budget fight to something with a larger market. The drug exists. Nobody is moving it.
Mendra, which launched in January 2026, is built on the observation that this is an allocation problem more than a chemistry problem. Rather than discover new compounds, the company scans the landscape of existing rare-disease assets, scores them, and acquires the ones it thinks it can push across the finish line. Then it develops and commercializes them. The company describes itself, plainly, as "AI-native biopharma for rare diseases."
What makes that pitch credible is not the AI - everyone says AI now - but the fact that the people involved have done the hard part before. CEO Joshua Grass spent roughly fifteen years at BioMarin, the company that turned commercializing therapies for tiny patient populations into an actual business, and then founded two more companies that were both acquired. The chief commercial officer, Jeff Ajer, was BioMarin's CCO and personally launched multiple rare disease therapies around the world. This is a team that knows exactly where the bodies are buried, because several of them helped bury the bodies.
The wrinkle is the CTO. Lalarukh Haris Shaikh came from Palantir, where she was an executive vice president running Life Sciences and Aerospace. That is not a typical biotech resume, and it is the tell. Mendra is trying to bring the kind of data-and-decision tooling Palantir sells to governments and banks into the messy, human problem of finding a few thousand patients scattered across the globe and getting them enrolled in a trial.
Because that is the genuinely hard problem in rare disease, and it is worth being precise about it. The molecule is often the easy part. The expensive, slow, failure-prone part is identifying who has the disease at all - many rare conditions are misdiagnosed for years - and then finding those patients, enrolling them, running a trial with a population so small that ordinary statistics strain, and finally convincing payers in dozens of countries to reimburse a therapy for a handful of people. Mendra's bet is that AI can compress the time and cut the waste out of each of those steps.
There is something almost contrarian in the mission statement. Mendra says it wants to "create pathways for scientists to develop cures for rare and ultra-rare disease without perpetual dependence on Pharma M&A." Read that twice. The usual endgame for a small rare-disease program is to get bought by a large pharmaceutical company - the acquisition is the exit, the point. Mendra is proposing to build the machinery that lets those programs advance without needing to be swallowed. It is, in a sense, a company designed to route around the incentive structure that funds it.
Which is a fine thing to say and a hard thing to do, and it is worth being honest about what Mendra is and is not at this stage. At launch it is nine people and no publicly disclosed drug. The $82 million is earmarked to go acquire the initial assets - the portfolio does not yet exist. So the investors who co-led the round, OrbiMed, 8VC, and 5AM Ventures, with Lux Capital and Wing VC alongside, were not buying a pipeline. They were buying judgment: a specific team's ability to look at thousands of stranded programs and reliably pick the ones worth rescuing.
That is a reasonable thing to underwrite, and it is also the whole risk. A roll-up is only as good as its scoring function, whether that function lives in a spreadsheet or a model. If Mendra's system for ranking assets is right, the company compounds; it keeps finding undervalued science and finishing it. If the system is wrong in some systematic way, it will efficiently acquire a portfolio of things that were shelved for good reasons. The interesting question - the one worth watching over the next couple of years - is which assets Mendra actually buys, and what that reveals about how its engine really works.
For now, the shape of the thing is clear enough. Mendra is trying to make rare disease drug development less dependent on luck and heroics and more like a repeatable process - one where the scarce resource being managed is not money or even science, but attention.
A senior team drawn from BioMarin, Palantir, and two acquired startups - heavier on track record than headcount.
20+ years in biopharma. About 15 years at BioMarin building its rare disease portfolio, then founded Modis Therapeutics and Escient Pharmaceuticals - both acquired.
Formerly EVP of Life Sciences and Aerospace at Palantir Technologies. Works at the intersection of life sciences, healthcare, and data platforms.
25+ years in global commercialization. Former CCO at BioMarin, where he built the commercial infrastructure and launched multiple rare disease therapies worldwide.
Previously led BD at Escient Pharmaceuticals, with earlier roles at Zogenix and Bayer, and time as a venture investor at Avego Bioscience Capital.
Leads operations for the early team, coordinating development and execution across Mendra's acquisition-driven model.
Building the data and AI tooling that powers Mendra's asset scoring, patient identification, and development workflows.
| Round | Amount | Date |
|---|---|---|
| Series A | $82,000,000 | January 2026 |
The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. Mendra was originally founded and incubated by 8VC and 5AM in 2025. The proceeds are meant to acquire and develop the company's first rare disease assets.
Solid bars = co-leads. Shorter bars = participating. Individual check sizes not disclosed.
AI systematically scans rare-disease assets across academia, small biotechs, and big pharma portfolios, then scores them to find where Mendra can add value.
Uses AI to speed patient identification, data curation, and clinical trial enrollment - the traditionally slowest steps in orphan-drug development.
Handles regulatory strategy, reimbursement planning, and worldwide market access to get approved therapies to patients and their families.
For researchers, biotechs, and patient foundations, that means a partner who can pick up a stranded program and carry it the rest of the way - the regulatory strategy, the trials, the payer negotiations - without the science having to be sold off to survive.
Mendra is founded and incubated by venture firms 8VC and 5AM to modernize rare disease drug development.
Mendra emerges from stealth with an oversubscribed $82 million Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with Lux Capital and Wing VC participating - earmarked to acquire its first assets.
Sources: Mendra.com, BusinessWire, BioSpace, BioPharma Dive, PitchBook, Global Genes, Inside Precision Medicine. Figures reflect Mendra's January 2026 launch and are approximate where noted.